SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026
Rhea-AI Summary
SenesTech (NASDAQ: SNES) will report fourth quarter and fiscal year 2025 financial results for the period ended December 31, 2025, after market close on Thursday, March 12, 2026. A conference call to review results will be held the same day at 5:00 p.m. Eastern.
Live webcast access and a replay will be available in the Investor Relations section of the company website for at least 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – SNES
In the Mar 10 session, SNES declined 6.60%, reflecting a notable negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Field study results | Positive | -1.1% | Multi‑month urban field results showing strong reductions in rodent activity with Evolve. |
| Feb 10 | Commercial strategy shift | Positive | -2.7% | Company taking direct control of Amazon sales for Evolve Rat and Evolve Mouse. |
| Feb 02 | Regulatory approval | Positive | +9.7% | New Zealand approval of Evolve fertility-control product and initial stocking shipment. |
| Jan 28 | Leadership transition | Negative | -1.1% | CEO retirement plan and appointment of Interim Executive Chair for continuity. |
| Nov 11 | International distribution | Positive | -8.2% | Belize Raptor Center added as international distributor for Evolve Rat Birth Control. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and strategic news has often seen flat-to-negative price reactions, with only regulatory approval in New Zealand showing a stronger positive move.
Over the past several months, SenesTech reported multiple operational milestones, including international expansion to New Zealand and Belize for its Evolve® rat birth control and positive urban field-study data showing substantial rodent-activity reductions. It also shifted Amazon sales for Evolve™ Rat and Mouse to direct management and announced a CEO transition effective by June 30, 2026. Price reactions were modest or negative for most announcements, with the New Zealand approval on Feb 2, 2026 the main positive outlier.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Financial results to be released after market close;
Conference call to be conducted at 5:00 p.m. Eastern time
Fourth Quarter and Fiscal Year 2024 Conference Call Details
Date and Time: Thursday, March 12, 2026, at 5:00 p.m. Eastern time
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://app.webinar.net/g3BpDpdDZ14 or http://senestech.investorroom.com/.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at http://senestech.investorroom.com/ for at least 90 days.
About SenesTech
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.
For more information, visit https://senestech.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to regain and maintain compliance with Nasdaq's continued listing requirements; and regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACT:
Investor: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-thursday-march-12-2026-302707177.html
SOURCE SenesTech, Inc.